• Clinical science

Sepsis

Summary

Sepsis is an acute life-threatening condition characterized by organ dysfunction due to a dysregulated immune response to infection. The previously widely used term “systemic inflammatory response syndrome” (SIRS) is now considered outdated because its criteria were too simplified. Initial infection is generally bacterial and commonly of respiratory, genitourinary, gastrointestinal, dermatological, or soft tissue origin. Risk factors include immunocompromise, chronic comorbidities (e.g., diabetes mellitus), young or old age, and lengthy or invasive medical care. Patients may present with fever, tachycardia, confusion, and signs of the primary infection. Organ dysfunction is determined using a sequential organ failure assessment (SOFA) score that considers multiple parameters, but may be quickly evaluated and assumed if two of the following findings are present: tachypnea, hypotension, and altered mental status. Diagnostic workup focuses on determining the responsible pathogen via cultures and identifying the source of infection (e.g., via imaging, ECG, lumbar puncture). Laboratory findings are largely nonspecific. Prompt, aggressive treatment is vital to survival and consists of resuscitation, empiric antibiotic therapy, and control of the infectious source.

Etiology

References:[1][2][3][4][5][6][7]

Classification

2015 criteria and SOFA classification (The third international consensus definitions for sepsis and septic shock, Sepsis-3)

Sequential Organ Failure Assessment score (SOFA score) [8][9]

Organ dysfunction and score 0 1 2 3 4

Respiration

PaO2/FiO2 (mmHg)

≥ 400 < 400 < 300 < 200 with respiratory support < 100 with respiratory support

Coagulation

Platelets x 103/mm3

≥ 150 < 150 < 100 < 50 < 20

Liver

Bilirubin (mg/dL)

< 1.2 1.2–1.9 2.0–5.9 6.0–11.9 > 12.0

Cardiovascular system

MAP ≥ 70 mmHg

MAP

< 70 mmHg

Dopamine < 5,

or dobutamine

(any dose)*

Dopamine > 5.1–15, or

epinephrine ≤ 0.1, or

norepinephrine ≤ 0.1*

Dopamine > 15, or

epinephrine > 0.1, or

norepinephrine > 0.1*

Central nervous system

Glasgow Coma Scale

15 13–14 10–12 6–9 < 6

Renal system

Creatinine (mg/dL) or urine output (mL/d)

< 1.2 1.2–1.9 2.0–3.4

3.5–4.9

or < 500

> 5.0

or < 200

Abbreviations: PaO2 = partial pressure of oxygen; FiO2 = fraction of inspired oxygen; MAP = mean arterial blood pressure

* Catecholamine doses are administered as μg/kg /min for ≥ 1 hour


References:[3][10][8][11][12][13]

Pathophysiology

An adequate immune response requires a balance between proinflammatory (anti-infectious) and anti-inflammatory signals!

Clinical features

References:[1][2][14]

Diagnostics

References:[15][1][2][3][12][16]

Treatment

In addition to immediate resuscitation and empiric therapy, the infectious focus must be identified and treated!
References:[15][1][2][17][18]

Complications

Critical illness polyneuropathy is a common cause of prolonged weaning from mechanical ventilation in a patient with sepsis!
References:[19]

We list the most important complications. The selection is not exhaustive.

Related One-Minute Telegram

Interested in the newest medical research, distilled down to just one minute? Sign up for the One-Minute Telegram in “Tips and links” below.

  • 1. Kalil A. Septic Shock. In: Septic Shock. New York, NY: WebMD. http://emedicine.medscape.com/article/168402. Updated March 17, 2016. Accessed February 21, 2017.
  • 2. Maggio PM. Sepsis and Septic Shock. http://www.merckmanuals.com/professional/critical-care-medicine/sepsis-and-septic-shock/sepsis-and-septic-shock. Updated April 1, 2016. Accessed February 21, 2017.
  • 3. Neviere R. Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/sepsis-syndromes-in-adults-epidemiology-definitions-clinical-presentation-diagnosis-and-prognosis. Last updated February 1, 2017. Accessed February 21, 2017.
  • 4. Gauer RL. Early Recognition and Management of Sepsis in Adults: The First Six Hours. Am Fam Physician. 2013; 88(1): pp. 44–53. url: http://www.aafp.org/afp/2013/0701/p44.html.
  • 5. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. . 2003; 348(16): pp. 1546–1554. doi: 10.1056/nejmoa022139.
  • 6. National Guideline Centre. Guideline summary: Sepsis: recognition, diagnosis and early management. https://guidelines.gov/summaries/summary/50412/sepsis-recognition-diagnosis-and-early-management. Updated July 13, 2016. Accessed December 1, 2017.
  • 7. Gauer RL. Early recognition and management of sepsis in adults: The first six hours. Am Fam Physician. 2013; 88(1): pp. 44–53. url: http://www.aafp.org/afp/2013/0701/p44.html#afp20130701p44-t1.
  • 8. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8): pp. 801–810. doi: 10.1001/jama.2016.0287.
  • 9. Marik PE, Taeb AM. SIRS, qSOFA and new sepsis definition. J Thorac Dis. 2017; 9(4): pp. 943–945. doi: 10.21037/jtd.2017.03.125.
  • 10. Balk RA. SIRS, Sepsis, and Septic Shock Criteria. https://www.mdcalc.com/sirs-sepsis-septic-shock-criteria#about-equation. Updated March 14, 2017. Accessed March 14, 2017.
  • 11. qsofa.org. What is qSOFA?. http://www.qsofa.org/what.php. Updated March 14, 2017. Accessed March 14, 2017.
  • 12. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003; 29(4): pp. 530–538. doi: 10.1007/s00134-003-1662-x.
  • 13. Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock for the Third International Consensus Definitions for sepsis and septic shock (sepsis-3). JAMA. 2016; 315(8): pp. 775–787. doi: 10.1001/jama.2016.0289.
  • 14. Saguil A, Fargo M. Acute Respiratory Distress Syndrome: Diagnosis and Management. Am Fam Physician. 2012; 85(4): pp. 352–358. url: http://www.aafp.org/afp/2012/0215/p352.html.
  • 15. Cunha BA. Bacterial Sepsis. In: Bacterial Sepsis. New York, NY: WebMD. http://emedicine.medscape.com/article/234587. Updated March 18, 2016. Accessed February 21, 2017.
  • 16. Meisner M. Update on procalcitonin measurements. Ann Lab Med. . 2014; 34(4): p. 263. doi: 10.3343/alm.2014.34.4.263.
  • 17. Schmidt GA, Mandel J, Parsons PE, Sexton DJ, Hockberger RS, Finlay G. Evaluation and Management of Suspected Sepsis and Septic Shock in Adults . In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/evaluation-and-management-of-suspected-sepsis-and-septic-shock-in-adults?. Last updated July 20, 2017. Accessed September 27, 2017.
  • 18. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017; 43(3): pp. 304–377. doi: 10.1007/s00134-017-4683-6.
  • 19. Hermans G, De Jonghe B, Bruyninckx F, Berghe G. Clinical review: critical illness polyneuropathy and myopathy. Critical Care. 2008; 12(6): p. 238. doi: 10.1186/cc7100.
  • Shortridge D, Castanheira M, Pfaller MA, Flamm RK. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. Antimicrobial Agents Chemother (Bethesda). 2017; 61(7). doi: 10.1128/aac.00465-17.
  • Gallagher JC, Satlin MJ, Elabor A, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study. Open Forum Infectious Diseases. 2018; 5(11). doi: 10.1093/ofid/ofy280.
  • Horcajada JP, Montero M, Oliver A, et al. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin Microbiol Rev. 2019; 32(4). doi: 10.1128/cmr.00031-19.
  • Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage Pseudomonas aeruginosa infections. Drugs in Context. 2018; 7: pp. 1–18. doi: 10.7573/dic.212527.
  • Cecconi M, De Backer D, Antonelli M, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014; 40(12): pp. 1795–1815. doi: 10.1007/s00134-014-3525-z.
  • Septimus EJ, Coopersmith CM, Whittle J, Hale CP, Fishman NO, Kim TJ. Sepsis National Hospital Inpatient Quality Measure (SEP-1): Multistakeholder Work Group Recommendations for Appropriate Antibiotics for the Treatment of Sepsis. Clinical Infectious Diseases. 2017; 65(9): pp. 1565–1569. doi: 10.1093/cid/cix603.
  • Kalil AC, Gilbert DN, Winslow DL, Masur H, Klompas M. Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines. Clinical Infectious Diseases. 2017; 66(10): pp. 1631–1635. doi: 10.1093/cid/cix997.
  • Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy. 2020; 77(11): pp. 835–864. doi: 10.1093/ajhp/zxaa036.
  • Herold G. Internal Medicine. Cologne, Germany: Herold G; 2014.
  • Rhee C, Chiotos K, Cosgrove SE, et al. Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure. Clinical Infectious Diseases. 2020. doi: 10.1093/cid/ciaa059.
  • Hernández G, Ospina-Tascón GA, Damiani LP, et al. Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock. JAMA. 2019; 321(7): p. 654. doi: 10.1001/jama.2019.0071.
  • Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 2018; 44(6): pp. 925–928. doi: 10.1007/s00134-018-5085-0.
  • Rello J, Kollef MH, Díaz E, Rodríguez A. Infectious Diseases in Critical Care. Springer Science & Business Media; 2010.
  • Saag MS et al. The Sanford Guide to Antimicrobial Therapy 2016. Sperryville: Antimicrobial Therapy, Inc; 2016.
  • Goldman L, Schafer AI. Goldman-Cecil Medicine, 2-Volume Set. Elsevier; 2019.
  • Walls R, Hockberger R, Gausche-Hill M. Rosen's Emergency Medicine. Philadelphia, PA: Elsevier Health Sciences; 2018.
  • Kortenoeven ML, Li Y, Shaw S, et al. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int. 2009; 76(1): pp. 44–53. doi: 10.1038/ki.2009.91.
  • Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015; 132(15): pp. 1435–1486. doi: 10.1161/CIR.0000000000000296.
  • Lee SM, An WS. New clinical criteria for septic shock: serum lactate level as new emerging vital sign. Journal of Thoracic Disease. 2016; 8(7): pp. 1388–1390. doi: 10.21037/jtd.2016.05.55.
last updated 09/11/2020
{{uncollapseSections(['nDb7UD', '6Dbj2D', 'pDbL2D', 'JDbs2D', 'qDbC2D', '7Db4fD', 'GDbBfD', 'tDbXTD', '3M1Soh0'])}}